SCHEMBL1433205

SCHEMBL1433205

O=C(c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F)C(Cl)(Cl)Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.66
ALDH1A1 P00352 5/20 0.64
CYP1A2 P05177 3/20 0.61
CYP2C9 P11712 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
MAPK1 P28482 1/20 0.60
POLB P06746 1/20 0.59
CYP2D6 P10635 2/20 0.57
LMNA P02545 2/20 0.57
CYP3A4 P08684 1/20 0.57
TSHR P16473 1/20 0.57
CYP2C19 P33261 1/20 0.57
CACNA1F O60840 1/20 0.57
KCNA5 P22460 1/20 0.57
SLC6A2 P23975 1/20 0.57
ADRA1A P35348 1/20 0.57
OPRK1 P41145 1/20 0.57
CACNA1D Q01668 1/20 0.57
KCNH2 Q12809 1/20 0.57
CACNA1S Q13698 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1433401 0.90 KDM4E (0.64) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
SCHEMBL14622160 0.85 ALDH1A1 (0.68) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
SCHEMBL3480459 0.85 KDM4E (0.69) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
SCHEMBL7694742 0.84 KDM4E (0.73) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
SCHEMBL978291 0.83 KDM4E (0.71) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
SCHEMBL7172752 0.82 ALDH1A1 (0.67) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
SCHEMBL1432938 0.82 ALDH1A1 (0.72) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
SCHEMBL11786444 0.82 KDM4E (0.69) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
Hydrochloric Acid SCHEMBL10754121 0.82 KDM4E (0.69) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2
SCHEMBL1434097 0.81 KDM4E (0.64) KDM4EALDH1A1CYP1A2CYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4675448-A Chlorination process ETHYL CORPORATION (US) 1987-06-23 US claimed
US-4642384-A Process for the preparation of derivatives of pyrrolidine and piperidine RIKER LABORATORIES, INC. (US) 1987-02-10 US claimed
JP-1125343-A None JP disclosed
JP-1125343-A None JP disclosed
EP-1907360-B1 IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE GLADE ORGANICS PRIVATE LTD (IN) 2011-03-30 EP disclosed
US-20100184990-A1 Process for the Manufacture of Flecainide GLADE ORGANICS PRIVATE LIMITED (IN) 2010-07-22 US disclosed
US-20100184990-A1 Process for the Manufacture of Flecainide GLADE ORGANICS PRIVATE LIMITED (IN) 2010-07-22 US disclosed
US-20100184990-A1 Process for the Manufacture of Flecainide GLADE ORGANICS PRIVATE LIMITED (IN) 2010-07-22 US disclosed
EP-1907360-A4 IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE GLADE ORGANICS PRIVATE LTD (IN) 2009-04-01 EP disclosed
EP-1907360-A1 IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE Glade Organics Private Limited (IN) 2008-04-09 EP disclosed
WO-2007003982-A1 IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE GLADE ORGANICS PRIVATE LIMITED (IN) 2007-01-11 WO disclosed
JP-H01125343-A 2,5-BIS(2,2,2-TRIFLUOROETHOXY)-ALPHA,ALPHA,ALPHA-TRICHLOROACETOPHENONE AND ITS PRODUCTION RIKER LAB INC 1989-05-17 JP disclosed
JP-H01125343-A 2,5-BIS(2,2,2-TRIFLUOROETHOXY)-ALPHA,ALPHA,ALPHA-TRICHLOROACETOPHENONE AND ITS PRODUCTION RIKER LAB INC 1989-05-17 JP disclosed
US-4675448-A Chlorination process ETHYL CORPORATION (US) 1987-06-23 US disclosed
US-4675448-A Chlorination process ETHYL CORPORATION (US) 1987-06-23 US disclosed
US-4650873-A Process for the preparation of a derivative of piperidine RIKER LABORATORIES (US) 1987-03-17 US disclosed
US-4642384-A Process for the preparation of derivatives of pyrrolidine and piperidine RIKER LABORATORIES, INC. (US) 1987-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184990-A1 Process for the Manufacture of Flecainide KCND2, KCNH1, KCNH2 KDM4E 478/4885ALDH1A1 960/4885CYP1A2 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.